text
"['\nIX. 계열회사 등에 관한 사항\n1.\xa0계열회사에 관한 사항\xa0(1)\xa0기업집단의 명칭 : 종근당그룹\xa0(2) 계열회사간 출자현황\n(2020.3.31 현재)\n회\xa0 사\xa0 명\n투자지분 현황\n비\xa0 고\n1\n(주)종근당홀딩스(113-81-06667)\n종근당산업(주) 57.55%, (주)벨이앤씨 42.38%,(주)벨커뮤니케이션즈 51.00%, 종근당건강(주) 51.00%,(주)경보제약 43.41%, (주)종근당바이오 37.25%,(주)종근당 24.37%, (주)벨아이앤에스 40.00%\xa0\n상장\n2\n(주)종근당(110-86-08069)\nPT CKD OTTO PHARMACEUTICALS 70.00%\n상장\n3\n종근당바이오(주)(110-81-53652)\nPacific Blue Health Pty Ltd 100.00%\n상장\n4\n(주)경보제약(312-81-04567)\nBardia Farma 100%\n상장\n5\n종근당산업(주)(110-81-07992)\n-\n비상장\n6\n(주)벨이앤씨(124-81-47431)\n-\n비상장\n7\n(주)벨커뮤니케이션즈(110-81-33831)\n-\n비상장\n8\n종근당건강(주)(134-81-29992)\n(주)텔라이프 50.00%, (주)에이뉴힐 100.00%Qingdao Zhong Gen Tang Health Co., Ltd 100.00%\n비상장\n9\nCKD창업투자(주)(306-81-29961)\n-\n비상장\n10\n(주)벨에스엠(107-86-80124)\n-\n비상장\n11\n(주)벨아이앤에스(110-81-82195)\n-\n비상장\n12\n(주)텔라이프(741-88-00832)\n-\n비상장\n13\n(주)에이뉴힐(773-87-01224)\n-\n비상장\n14\nBardia Farma SPA\n-\n해외법인\n15\nPT CKD OTTO PHARMACEUTICALS\n-\n해외법인\n16\nPacific Blue Health Pty Ltd(구 CKDBio Australia Pty Ltd)\n-\n해외법인\n17\nQingdao Zhong Gen Tang Health Co., Ltd\xa0\n-\n해외법인\n2. 타법인 출자현황\n[2020. 3. 31 현재]\n(단위 : 주, 백만원, 천달러, 백만루피아, %)\n법인명\n출자목적\n기초잔액\n증가(감소)\n당분기말 잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n한국능률협회컨설팅(비상장)\n단순투자\n39,195\n4.9\n196\n-\n-\n-\n39,195\n4.9\n196\n70,406\n6,770\n매일방송(비상장)\n""\n542,210\n1.0\n2,623\n-\n-\n-\n542,210\n1.0\n2,623\n392,574\n5,633\n코리아이플랫폼(비상장)\n""\n116,659\n1.6\n1,084\n-\n-\n-\n116,659\n1.6\n1,084\n150,564\n2,481\n씨앤비인터내셔널(비상장)\n""\n30,000\n10.0\n1,621\n-\n-\n-\n30,000\n10.0\n1,621\n10,269\n218\nKC상생투자조합\n""\n-\n2.4\n1,000\n-\n-\n-\n-\n2.4\n1,000\n41,287\n(932)\nCARA (미국_상장)\n""\n75,597\n0.2\n1,410\n-\n-\n(189)\n75,597\n0.2\n1,221\n$232,959\n($106,373)\nZafgen(미국_상장)\n""\n171,750\n0.5\n221\n-\n-\n(59)\n171,750\n0.5\n162\n$80,734\n($45,406)\n(주)한미약품(상장)\n""\n2,135\n0.0\n633\n42\n-\n(64)\n2,177\n0.0\n569\n1,544,610\n24,257\nBioMX(미국_상장)\n""\n499,324\n2.2\n5,599\n-\n-\n(1,326)\n499,324\n2.2\n4,273\n$92,121\n($20,563)\n동양레저(비상장)\n""\n20,000\n0.6\n100\n-\n-\n-\n20,000\n0.6\n100\n58,268\n5,900\nRMGP Bio Pharma(비상장)\n""\n-\n18.9\n3,301\n-\n231\n-\n-\n18.9\n3,532\n$19,654\n$1,977\nCKD-BS Start-Up벤처투자조합\n""\n-\n3.4\n340\n-\n-\n-\n-\n3.4\n340\n9,183\n720\nPT CKD OTTO PHARMACEUTICALS(인도네시아_비상장)\n합작\n100,800,000\n70.0\n3,344\n-\n-\n(1,504)\n100,800,000\n70.0\n1,840\nIDR 291,410\n(IDR 33,694)\n합 계\n-\n-\n21,472\n-\n231\n(3,142)\n-\n-\n18,561\n-\n-\n※\xa0당분기말 현재 해당 법인에 대한 출자비율이 5% 미만이거나, 장부가액이 1억원 미만인 경우 기재를 생략하였습니다.\n']"
